108781-14-2

Upstream product

• 100-83-4 meta-hydroxybenzaldehyde 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 108781-15-3 3-(p-methoxybenzyloxy)benzylidenemalonic acid diethyl ester 
• 1236355-45-5 2-methylthio-(E,E)-4,6-bis-(3'-hydroxystyryl)pyrimidine 
• 1396037-16-3 2-methylthio-(E,E)-4,6-bis[3'-(4''-methoxybenzyloxy)styryl]pyrimidine 
• 1236355-39-7 2-methoxy-(E,E)-4,6-bis-(3'-hydroxystyryl)pyrimidine 
• 1396036-85-3 2-methoxy-(E,E)-4,6-bis[3'-(4''-methoxybenzyloxy)styryl]pyrimidine 
• 1396036-57-9 (E,E)-4,6-bis[3'-(4''-methoxybenzyloxy)styryl]pyrimidine 
• 209120-06-9 {1-Fluoro-2-[3-(4-methoxy-benzyloxy)-phenyl]-ethyl}-phosphonic acid diethyl ester 
• 209120-15-0 [1-Fluoro-2-(3-hydroxy-phenyl)-ethyl]-phosphonic acid diethyl ester 
• 336193-99-8 3-(4-Methoxybenzyloxy)benzonitrile 
• 104-21-2 p-methoxybenzyl acetate 
• 100-83-4 meta-hydroxybenzaldehyde 

Relevant academic research and scientific papers

INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR

Chromanone compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the inhibition of antigen presentation by HLA-DR.

Small molecules that protect against β-amyloid-induced cytotoxicity by inhibiting aggregation of β-amyloid

Aggregated β-amyloid (Aβ) plays crucial roles in Alzheimer's disease (AD) pathogenesis, therefore blockade of Aβ aggregation is considered as a potential therapeutic target. We designed and synthesized small molecules to reduce Aβ-induced cytotoxicity by inhibiting Aβ aggregation. The small molecules were screened via ThT, MTT, and cell-based cytotoxicity assay (Aβ burden assay). Selected compounds 1c, 1d, 1e, and 1f were then investigated by evaluating their effects on cognitive impairment of acute AD mice model. Learning and memory dysfunction by injection of Aβ(1-42) was recovered by administration of these molecules. Especially, 1d showed the best recovery activity in Y-maze task, object recognition task, and passive avoidance task with dose dependent manner. These results suggest that 1d has high potential as a therapeutic agent for AD.

Irreversible dopamine-β-hydroxylase inhibitors

Potent, irreversible dopamine-β-hydroxylase inhibitors having the Formula: STR1 which are useful to inhibit dopamine-β-hydroxylase activity, pharmaceutical compositions including these inhibitors or 2-cyano-2-phenethylamine, and methods of using these inhibitors or 2-cyano-2-phenethylamine to inhibit dopamine-β-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.